1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

5.02
HKD
-0.36
(-6.70%)
5.01BMarket Cap
Mar 24Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
1.28
0.2
0.13
0.08
0.2
0.07
- -
Basic EPS, GAAP
-0.2
-0.56
-3.97
-0.4
-0.49
-0.46
-0.2
-0.19
- -
Free Cash Flow per Basic Share
-0.13
-0.15
0.18
-0.21
-0.41
-0.52
-0.11
-0.27
- -
Dividend per Share
0.02
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.13
-0.62
2.35
2.12
1.66
1.36
1.17
0.98
0.98
Tangible Book Value per Share
-0.13
-0.62
2.35
2.12
1.66
1.35
1.17
0.98
0.98
Basic Weighted Avg Shares
760
760
381
747
752
773
775
775
781
Sales/Revenue/Turnover
- -
- -
486
153
96
64
156
54
- -
Operating Margin (%)
- -
- -
43.06
-197.84
-494.76
-642.68
-130.5
-310.58
- -
Depreciation Expense
9
13
8
11
14
25
26
23
- -
Net Income, GAAP
-149
-425
-1,514
-301
-372
-359
-156
-146
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-311.27
-197.1
-388.38
-565.36
-100
-272.73
- -
Working Capital
407
272
1,741
1,559
1,183
963
946
927
927
LT Debt
15
11
2
2
135
122
86
150
150
Total Equity
-97
-470
1,786
1,637
1,283
1,073
923
771
771
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-17.6
-25.47
-30.49
-15.6
-17.24
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
66
26
15
LT Borrowings
16
52
89
LT Finance Leases
70
65
61
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
789
789
787
Market Capitalization
941
3,124
4,505

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,189
1,132
1,154
Cash, Cash Equivalents & STI
1,175
1,074
1,104
Accounts Receivable, Net
8
51
9
Inventories
- -
- -
- -
Total Current Liabilities
243
150
226
Payables & Accruals
- -
- -
- -
ST Debt
66
26
15
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-15.37%
-16.52%
Free Cash Flow
- -
-28.09%
146.74%
Net Income, GAAP
- -
-24.59%
-6.25%
Sales/Revenue/Turnover
- -
-12.01%
-65.62%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
64
2024
- -
- -
156
2025
- -
- -
54

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.46
2024
- -
- -
-0.2
2025
- -
- -
-0.19

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yinxiang Wang
Full Time Employees
196
Sector
Health technology
Industry
Biotechnology
Address
Building F2 Beijing BE China 101111
IPO Date
Dec 21, 2020
Website
jacobiopharma.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Jacobio Pharmaceuticals Group Co., Ltd. is a China-based biopharmaceutical company primarily engaged in the research, development, manufacture, and commercialization of innovative drugs. Its main products and services include targeted cancer therapies, small molecule drugs, and biologics with a focus on oncology, autoimmune diseases, and infectious diseases. The company operates across China and markets its products domestically and internationally. Founded in 2007 and headquartered in Shanghai, Jacobio offers a portfolio that includes proprietary drug candidates, as well as contract development and manufacturing services within the pharmaceutical sector. Recent major company changes include strategic partnerships and the expansion of its product pipeline through new drug launches and developments in immuno-oncology and antiviral therapies. In the past 1-2 years, Jacobio has enhanced its R&D capabilities and broadened its geographic reach through collaborations with international pharmaceutical and biotech firms, reflecting a significant business expansion and diversification in its therapeutic offerings. The company maintains a strong commitment to innovation and aims to meet global medical needs through advanced pharmaceutical solutions. Jacobio Pharmaceuticals operates under the biotechnology and pharmaceutical industry segments, targeting hospitals, healthcare providers, and research institutions. Its subsidiary and alliance networks support its mission to develop cutting-edge treatments, aligning with global healthcare trends and regulatory standards. The company's focus on high-value drug candidates and strategic collaborations positions it as a competitive player in both domestic and global pharmaceutical markets.

Company News

Company News APIChatGPT